BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), an advanced digital signal processing technology
company delivering unprecedented accuracy and precision to
intracardiac signal visualization with its proprietary PURE EP™
System, today announced the release of PURE EP™ Software Version 6
with ACCUVIZ™ Module.
Built around three highly differentiating features, PURE EP™
Software Version 6 with ACCUVIZ™ Module introduces the proprietary
High Frequency Algorithm (HFA), a novel feature that identifies the
key frequency components of cardiac data that can be difficult to
identify within the traditional waveform presentation. Other unique
software functionalities— including Automatic Tachycardia
Characterization (ATC) and TRUSOURCE Analysis & Report—aim
to improve clinical workflow and deliver clear, actionable insights
to today's electrophysiologist.
PURE EP™ Software Version 6 with ACCUVIZ™ Module is the first to
be designed and launched by the Company’s new commercial and
operations team and represents the most advanced iteration of the
Company’s digital signal processing technology. Software Version 6
delivers a new level of efficiency enabling unlimited, real-time
analysis of intracardiac signals. In addition, the new ACCUVIZ™
Module introduces advanced signal processing automation, elevated
visualization of clear cardiac signal information, and even smarter
workflows.
“PURE EP™ Software Version 6 with ACCUVIZ™ Module acquires raw
intracardiac signals in their digital form to provide a new level
of efficiency and automaticity. I view this as a milestone in the
clinical evolution of our technology, and a testament to our
mission to provide our customers with actionable insights,”
commented Gray Fleming, Chief Commercialization Officer, BioSig
Technologies, Inc.
BioSig will introduce the newest software version of its PURE
EP™ System to customers—for the first time—at the annual Cleveland
Clinic Global EP Summit 2022. The annual symposium is taking place
this Friday-Saturday, September 23-24, 2022, in Cleveland, Ohio.
The Company has been invited to attend the world-class leadership
symposium as a platinum sponsor for the event.
About the Global EP Summit
The Global EP Summit is annual forum convening over 40 global EP
experts to highlight the latest research, technological
advancements, and state of the art practices in the field of
arrhythmia management. Co-sponsored by the Cleveland Clinic and the
Heart Rhythm Society, the 1.5-day program is designed for, but not
limited to, cardiologists, electrophysiologists, cardiovascular
fellows, electrophysiology fellows, nurses, PAs and all healthcare
providers involved in the care of arrhythmia patients.
About BioSig Technologies
BioSig Technologies, Inc. is an advanced digital signal
processing technology company bringing never-before-seen insights
to the treatment of cardiovascular arrhythmias. Through
collaboration with physicians, experts, and healthcare leaders
across the field of electrophysiology (EP), BioSig is committed to
addressing healthcare’s biggest priorities — saving time, saving
costs, and saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical study
recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with a
11.2% growth rate.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Andy Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024